What's the forecast for the CSL share price in the second half of 2023?

The biotech giant has seen its stock go sideways since COVID-19 struck. Is it ready for a post-pandemic push upwards?

| More on:
Two laboratory researchers in white coats and gloves sit side by side with scientific equipment and a computer screen conducting medical related research.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Australian biotechnology giant CSL Limited (ASX: CSL) has made many investors wealthy over the decades, but it's been a struggle in recent times.

The brutal reality is that the share price is still 10% lower than its pre-COVID high.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

So has the healthcare stock passed its heyday, or are there brighter times ahead?

Let's take a look:

Poised for a break-out year

Morgans analysts reckon CSL shares are a buy, predicting a post-pandemic revival in the business and the stock price.

"We believe CSL is poised to break-out this year," they stated, according to The Motley Fool's James Mickelboro.

"A COVID-exit trade… offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares offering good value trading around its long-term forward multiple of ~30x."

The team has a handy 11.6% upside to the stock price over the next 12 months.

Another interesting endorsement is that CSL is currently the fifth most held stock among millionaires, according to investment platform Selfwealth Ltd (ASX: SWF).

"Our millionaire portfolio investors hold strong companies in strong sectors," said Selfwealth chief executive Cath Whitaker.

Big investors are bullish on CSL

Finally, there are plenty of institutional investors that are backing the biotech business.

The Motley Fool's Tristan Harrison reported this week that Australian Foundation Investment Co Ltd (ASX: AFI), Argo Investments Limited (ASX: ARG), and Washington H. Soul Pattinson and Co. Ltd (ASX: SOL) all hold significant stakes in CSL.

"Argo and AFIC are two of the ASX's largest and oldest listed investment companies. They focus on ASX blue chip shares that can provide a mixture of dividends and capital growth," Harrison said.

"At the end of April, CSL shares were the third largest position in the AFIC portfolio, with an 8.1% weighting. CSL was also the third largest position in the Argo portfolio, with a 5.2% holding at the end of April."

The CSL share price is up 10.5% over the past year and 7.5% higher year to date.

Motley Fool contributor Tony Yoo has positions in CSL and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has positions in and has recommended Washington H. Soul Pattinson and Company Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »